Clinical trials: Obese Diabetics
Pre-Diabetic, Overweight
Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors
Purpose : Test the feasibility (acceptability, adherence) of a home-based interval exercise training (IET) and nutrition program, as well as its preliminary effects on resting heart rate, blood pressure, fasting glucose, HDL…
- Conditions
- Pre-Diabetic, Overweight, Obesity
- Trial name
- IETnutrition (NCT02482922)
- Testing
- Exercise & Dietary Supplement
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Obesity, Diabetes Mellitus Type 2
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 36 weeks in obese type 2 diabetic patients inadequately…
- Trial name
- SOLO (NCT00478972)
- Testing
- Rimonabant, Diet and exercise
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Insulin Sensitivity, Obesity
Comparative the Effect of Metformin and Acupuncture on Weight Loss and Insulin Sensitivity
The investigators designed this randomized double blind (patients/ assessor) clinical trial to compare the therapeutic effects of Metformin monotherapy with Metformin and acupuncture combined therapy on weight loss and insulin…
- Trial name
- NCT02438540
- Testing
- metformin, acupuncture
- Volunteers
- 43 people
- Sponsor
- Amir Firouzjaei
Obesity, Diabetes Mellitus, Type 2
A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin
The purpose of this study is to evaluate the effectiveness and safety of a topiramate controlled-release formulation in the treatment of obese, type 2 diabetic patients managed with diet alone or combined with metformin.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231647
- Testing
- topiramate
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus Type 2 in Obese
The GATE Trial: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina Device
Rationale: Diabetes mellitus is a chronic disease that is often associated with long-term macrovascular and microvascular complications and decreased life expectancy.
- Trial name
- GATE (NCT05711043)
- Testing
- Endoscopic sutured gastroplasty with endomina
- Where
- Netherlands
- Volunteers
- 58 people
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes, Obesity
Resveratrol in Type2 Diabetes and Obesity
The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2…
- Conditions
- Type 2 Diabetes, Obesity, Insulin Resistance
- Trial name
- NCT01158417
- Testing
- Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Obesity
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
- Trial name
- NCT00677391
- Testing
- Sibutramine
- Volunteers
- 103 people
- Sponsor
- Abbott
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Type 2 Diabetes, Hypertension
Health Effects of Recreational Soccer in Type 2 Diabetic Men
The present study investigates the effects of recreational soccer in type 2 diabetic men in regard to muscular, cardiovascular adaptations and glycaemic control.
- Conditions
- Type 2 Diabetes, Hypertension, Obesity, Metabolic Syndrome
- Trial name
- NCT01636349
- Testing
- soccer exercise or continued daily lifestyle
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Copenhagen
Cardiomyopathy
Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery
The overall purpose of this study is to evaluate the effect of gastric bypass surgery-induced weight loss on the heart's function and on fat deposits in the heart muscle.
- Trial name
- DRTC (NCT01067209)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Insulin Sensitivity
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
- Trial name
- Eritoran2 (NCT02267317)
- Testing
- Eritoran, D5W
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Overweight or Obesity
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the…
- Trial name
- NCT07294235
- Testing
- BGM1812
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Hypertension, Obesity
Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
The goal of this study is to build a mathematical model to explain the effect of two doses of azilsartan (40 and 80 mg) upon metabolic (insulin resistance, glucose) and inflammatory parameters (cytokines) in function of…
- Conditions
- Hypertension, Obesity, Type 2 Diabetes Mellitus
- Trial name
- NCT02235519
- Testing
- Azilsartan 40 mg., Azilsartan 80 mg
- Where
- Mexico
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Pre Diabetic, Obesity & Overweight
PREdiabetes GLycemic Impact and Data Evaluation
This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring…
- Conditions
- Pre Diabetic, Obesity & Overweight, Insulin Resistance
- Trial name
- PRE-GLIDE (NCT07599072)
- Testing
- CGM Sibionics, On-Call Extra Glucometer
- Where
- 3 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Nazarii Kobyliak
Obesity, Diabetes Mellitus Type 2
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in obese type 2 diabetic patients on monotherapy…
- Trial name
- SYMPHONY (NCT00478595)
- Testing
- Rimonabant, Anti-diabetic monotherapy
- Where
- Japan
- Volunteers
- 458 people
- Sponsor
- Sanofi
Weight Loss, Obesity
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying.
- Trial name
- NCT00856609
- Testing
- Byetta (exenatide), Weight loss, Metabolic Chamber
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients, Obesity &Amp; Overweight
Coronary Flow Reserve Changes After Semaglutide Treatment
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients.
- Trial name
- NCT07190144
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Ekrem Bilal Karaayvaz
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich
Type II Diabetes Mellitus
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides.
- Trial name
- NCT02274740
- Testing
- LIXISENATIDE AVE0010, metformin
- Volunteers
- 2 people
- Sponsor
- Sanofi